In primary tumors, PCa-derived CXCL16 recruits CXCR6-expressing MSCs which upregulate PCa CXCR4 expression, induce EMT markers via CXCL12 secretion, and promote tumor growth in vivo in a subcutaneous model (154). Here, CXCL16 is linked to posterior cortical atrophy.